Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038454 (stroke)
 147,016 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A patent foramen ovale (PFO) is an embryological remnant found in 27% of adults. It is a potential right-to-left intracardiac shunt. Shunting may be the result of reversal in the interatrial pressure gradient or abnormal streaming of blood in the right atrium. The pathologic consequences of right-to-left shunting include hypoxemia and paradoxical embolism. PFO may exacerbate preexisting hypoxemia or be its primary cause. Paradoxical embolism through a PFO is well documented. Its role in cryptogenic stroke remains controversial. A PFO may be detected by both invasive and noninvasive techniques. Contrast transesophageal echocardiography with provocative maneuvers is the diagnostic method of choice allowing visualization of the shunt. Patients with cryptogenic stroke should be screened for a PFO. If detected, noninvasive studies for deep vein thrombosis are recommended. Treatment must be tailored to the presentation. Surgical or transcatheter closure is recommended for hypoxemia. Prevention of venous embolism (air or thrombus) with or without closure of the PFO is recommended for paradoxical embolism.
 ...
PMID:Patent foramen ovale: a nonfunctional embryological remnant or a potential cause of significant pathology? 162 17

Deep vein thrombosis (DVT) is a potentially life-threatening problem for both medical and surgical patients. The rehabilitation client is at high risk of developing DVT. Conditions such as spinal cord injury, paraplegia, cerebrovascular accident, and total hip replacement place patients at risk for developing DVT. Unfortunately, few articles that address nursing interventions for this problem in the rehabilitation population have been written. This article examines the scope of the problem and its causes, pathogenesis, risk factors, and signs and symptoms from a rehabilitation nursing perspective.
 ...
PMID:Deep vein thrombosis in the rehabilitation client. 163 99

A total of 503 consecutive cases of suspected stroke were examined for potential eligibility based on recent development of a paralyzed limb. Of 123 otherwise eligible subjects, 22 were found by ultrasound to have deep vein thrombosis (DVT) on admission. Therefore, 101 patients were assigned randomly to one of the treatment groups or to the control group. The three treatments were adjusted-dose heparin, external pneumatic compression and functional electrical muscle stimulation. An ultrasound examination of the lower extremities was conducted twice a week on each patient until completion of the study (28 days or discharge, whichever came first). Electrical muscle stimulation was discontinued after 4 mo of the study because of discomfort, blister formation and high drop-out rate. Ten patients developed DVT during the study period. In 17 of the 32 cases of DVT, venography was performed, which confirmed the ultrasound findings in every case. The 32 cases of DVT differed from those without DVT by having a higher prevalence of hypertension (P = 0.02), cholesterol (P = 0.08) and a longer time interval between stroke and admission (P less than 0.05). We conclude that ultrasound is effective for DVT detection in the rehabilitation setting, and two-thirds of such cases are detectable on admission.
 ...
PMID:Deep vein thrombosis in rehabilitating stroke patients. Incidence, risk factors and prophylaxis. 174 2

Pulmonary embolism secondary to deep vein thrombosis is a frequent cause of death in stroke patients. In a multicentre study of deep vein thrombosis prophylaxis, 112 patients with cerebral infarction and leg paresis were given aspirin 300 mg three times a day (t.d.s.) alone or with dipyridamole 100 mg t.d.s. To screen for deep vein thrombosis liquid crystal thermography of the legs was performed daily for 15 days on all patients. Those patients with positive thermography underwent immediate X-ray venography of the appropriate limb as the definitive investigation for venous thrombosis. Twenty-two patients had positive thermograms, of whom 16 had confirmed deep vein thrombosis as demonstrated by X-ray venography. Only 8 of the 22 had clinical signs of deep vein thrombosis and 2 of those had a negative venogram. Of the 14 patients with positive thermography but negative clinical signs 10 had positive venograms. Difference in the incidence of deep vein thrombosis in the two treatment groups was not demonstrated. It is concluded that occult deep venous thrombosis is common after ischaemic stroke and it can occur without clinical signs. Liquid crystal thermography is a simple, rapid and cheap screening test that will allow the detection of clinically unrecognized thrombosis.
 ...
PMID:Liquid crystal thermography as a screening test for deep vein thrombosis in patients with cerebral infarction. 175 94

Though pulmonary embolism (PE) has been thought to be rare, the incidence seems to be increasing recently. During the past 10 years the authors have encountered 5 cases of PE among stroke patients. There were 2 males and 3 females, aged 51 to 71 years (mean age; 63 years). The mean time between admission and onset of PE was 23 days. As to the primary disease to be treated, 5 patients had subarachnoid hemorrhage and one had intracerebral hemorrhage. Generally, PE tends to be overlooked or misdiagnosed because of the fact that stroke patients are often in a state of unconsciousness. In our series, only one patient complained of dyspnea and the other 4 patients due to unexplained sudden tachycardia, tachypnea and hypoxemia were suspected to have PE. Deep venous thrombosis known as the risk factor leading to PE was presented in 3 patients. Especially in one patient, femoral venous catheterization was considered as a risk factor possibly leading to deep venous thrombosis. Regarding the diagnosis of PE, the roles of electrocardiogram and of chest x-ray film were small. In 3 patients, the elevation of the diaphragm was the only abnormal finding on chest X-ray. On the other hand, the lung scintigram with 99mTc-MAA was a useful method for definitive diagnosis of PE. In 3 patients, filling defects were demonstrated on the lung perfusion scintigrams. Consequently, we emphasize that PE must be kept in mind when tachycardia, tachypnea and hypoxemia appear suddenly. Prompt diagnosis and treatment are required.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Pulmonary embolism complicated with stroke: analysis of 5 cases]. 189 17

The development and widespread availability of noninvasive testing have revolutionized the approach to the diagnosis of vascular disease. Noninvasive tests are safe, can be performed on an outpatient basis, and are readily repeatable. These tests require skill and experience to perform with acceptable accuracy. In experienced hands, they compare favorably with standard angiography, and, after the initial cost, are less expensive. B-mode ultrasonography provides a gray scale image of the blood vessels. Doppler probes permit analysis of flow patterns and velocity. Color flow imaging, the latest advance, combines high-resolution B-mode and Doppler imaging systems using a computer to provide simultaneous anatomic and physiologic information. This method is a faster and more accurate means of detecting and evaluating the extent of vascular disease. Noninvasive testing is useful in assessing the carotid arteries before vascular or other high-risk operation. Stratification of the risk of future stroke is possible with these tests. This stratification assists in the selection of candidates for carotid surgery among patients with symptomatic carotid disease or asymptomatic bruits in the neck. The hemodynamic significance of obstructive disease in the peripheral arteries can be evaluated and followed by serial noninvasive testing. Noninvasive testing is also of proven value in the surveillance of patients with arterial bypass grafts and in diagnosing local vascular complications of arterial catheterization. Acute and recurrent deep venous thrombosis can be diagnosed accurately by noninvasive testing, greatly reducing the need for venography. In addition, noninvasive testing is particularly suited for screening patients at high risk for developing deep venous thrombosis.
 ...
PMID:Use of noninvasive vascular laboratory in diagnosis of venous and arterial disease. 191 25

The effect of LMW heparin (Kabi 2165, Fragmin) was compared with placebo for the prevention of DVT in 103 patients with acute ischemic stroke using a prospective, double-blind, randomized trial design. Treatment was started within 72 hours, and LMW heparin was administered subcutaneously once daily according to body weight classes, which corresponded to about 55 to 65 Factor-Xa inhibitory U/kg, for 14 days, or until discharge from the hospital, if earlier. All patients underwent thrombosis surveillance with unilateral venography of the paretic limb. Evaluation of venography could be performed in 42 of 52 patients randomized to LMW heparin and in 50 of 51 patients randomized to placebo. The frequency of DVT was 15 of 42 patients or 36% (95% confidence interval 22 to 52%) in the LMW heparin group and 17 of 50 patients or 34% (21 to 49%) in the placebo group. The frequency of proximal thrombi was 5 of 42 (12%) and 8 of 50 (16%), respectively. There was one fatal pulmonary embolism in the placebo group. The mortality rate (28 days follow-up) was 5 of 52 in the LMW heparin group and 1 of 51 in the placebo group (p = 0.24). None of the deaths was related to treatment. No major hemorrhagic complications were observed. The mean Factor Xa inhibitory activity levels at peak concentration were 0.34 U/ml on day 2 and 0.42 U/ml on day 12 (p = 0.02). We conclude that LMW heparin in the dose range studied did not provide efficient prophylaxis against DVT in patients with acute ischemic stroke.
 ...
PMID:A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. 196 1

In 539 consecutive stroke patients admitted to a rehabilitation department, we studied the possible role of atrial fibrillation as a risk factor for deep venous thrombosis and pulmonary embolism by analyzing a series of relevant clinical data in patients with and without atrial fibrillation and in patients with and without venous thromboembolic complications. Deep venous thrombosis as well as advanced age and cardiac disease were significantly (p less than 0.001) more frequent in patients with atrial fibrillation. However, in a model of simultaneous logistic regression carried out on the presence of absence of venous thromboembolic complications, atrial fibrillation was the only significant risk factor. In view of the morbidity and mortality linked to deep venous thrombosis, our findings argue for preventive anticoagulation therapy in stroke patients suffering from atrial fibrillation and merit further study.
Stroke 1991 Jun
PMID:Atrial fibrillation as a risk factor for deep venous thrombosis and pulmonary emboli in stroke patients. 205 76

In patients with ischemic stroke the risk of provoking hemorrhagic infarction must be balanced against the risk of deep vein thrombosis and potential pulmonary thromboembolism. In a retrospective study we reviewed the records of 262 ischemic stroke patients admitted in 1984 and of 315 patients admitted in 1988. In 1984 only six (2.3%) patients were treated with low-dose subcutaneous heparin, while 126 (40%) in 1988. In 1984 seventy-five (28.6%) patients died and in 48 of them post-mortem examination was performed, while in 1988 seventy-four (23.5%) patients died and in 30 of them the autopsy was performed. Pulmonary embolism was revealed in 25 patients on post-mortem examination in 1984 and none of them was treated with heparin. In 1988 only eight patients (two were on heparin) had pulmonary embolism. Hemorrhagic infarction was found in only seven cases (only two of them were on heparin) of all pathological examinations. We conclude that preventive low-dose subcutaneous heparin is safe and effective in decreasing mortality due to pulmonary embolism in patients with ischemic stroke.
 ...
PMID:Low-dose subcutaneous heparin decreases mortality from pulmonary embolism in patients with ischemic stroke. 207 30

Defibrotide, a deoxypolyribonuclide, has been found to modulate endothelial cell function causing increase in t-PA and decrease in PAI levels and also increase in PGI2 production. In addition, it increases platelet c-AMP levels and decreases MDA and TXB2 formation in human. Defibrotide inhibits platelet aggregate formation in vitro experiments as well as end-to-end anostomosis in rats. So, defibrotide inhibits the activation of platelets. Besides an increase of protein C and S levels a synergic action of heparin was observed in animal experiments. A strong antithrombotic effect has been observed in animal models. The drug has a beneficial effect in the cases of DVT, POVD, stroke and thromboembolism. Through its action we may say that the drug acts in a novel fashion in contrast to the other drugs used in this area. Defibrotide is a single-stranded polydeoxyribonucleotide obtained from deoxyribonucleic acid of mammalian lungs by controlled depolimerization. Since 1981 in our laboratory and in the clinical department we have been investigating a newly developed agent defibrotide in vitro experiments, animal experiments, and also its clinical pharmacology and clinical application. Some of our findings are already published and compared with literature (40, 43, 46). Because of the limited space we are not going to review the literature in detail but we are going to summarize our observations on this compound in the following order. I--in vitro experiments, II--Animal experiments, III--clinical pharmacology in human.
 ...
PMID:The pharmacology and clinical pharmacology of defibrotide: a new profibrinolytic, antithrombotic and anti-platelet substance. 210 24


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>